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ABSTRACT
The gut microbiome is a complex, biochemically rich and essential 
component of the human metabolic system. It has been our 
understanding for very long that the gut microbes are primarily there 
to digest the undigested food (mainly fibers), get nourishment, and 
in return release metabolites helping host cells — short-chain fatty 
acids produced by gut microbes are a great source of energy for the 
colonocytes. It is only in the last decade, with advancements of DNA 
sequencing platforms, that we are lettered about the association 
between the gut microbial composition and metabolic disorders such 
as obesity, dysglycemia, dyslipidemia, and cardiovascular diseases. 
This creates a momentum to understand the factors shaping the 
composition of the gut-microbiome, nature of dysbiosis (perturbation 
of gut microbial composition) associated with human health and ways 
to modulate the gut microbiome to achieve the desired health benefits
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GUT MICROBIOME AND METABOLIC 
SYNDROME
The gut microbiome is a complex, biochemically rich 
and essential component of the human metabolic 
system.1 It has been our understanding for very long 
that the gut microbes are primarily there to digest the 
undigested food (mainly fibers), get nourishment, 
and in return release metabolites helping host cells — 
short-chain fatty acids produced by gut microbes are 
a great source of energy for the colonocytes.2,3,4 It is 
only in the last decade, with advancements of DNA 
sequencing platforms, that we are lettered about the 
association between the gut microbial composition 
and metabolic disorders such as obesity, dysglyce-
mia, dyslipidemia, and cardiovascular diseases.5,6,7 
This creates a momentum to understand the factors 
shaping the composition of the gut-microbiome, 
nature of dysbiosis (perturbation of gut microbial 
composition) associated with human health and 
ways to modulate the gut microbiome to achieve the 
desired health benefits.8,9,10 
DIET, A PREDOMINANT FACTOR 
SHAPING THE GUT MICROBIOME 
Since microbes colonize gut mainly for nutrients, 
diet was hypothesized to be one of the predominant 
factors shaping the gut microbial composition. In 
last few years, this hypothesis was tested by multiple 
individual groups and reported a direct association 
between specific diet-types and gut microbial compo-
sition.1,11,12,13,14 Jansson/Tanja et al15 have found that 
a diet rich in resistant starch (RS) modulates the 
Firmicutes and Bacteroidetes ratio. A comparison 
of animal and plant based diet has shown that even 
a short term perturbation of diet may change the 
composition of the gut microbiome, and animal-
based diet boosts the abundance of  bile-tolerant 
microbes and decreases Firmicutes which uses 
polysaccharides from plant sources.16 Similar obser-
vation of quick changes in microbial composition 
has been found through the Western-diet (high Fat 
and Sugar).17 Therefore, a dietary modulation of 
gut-microbiome to treat above discussed metabolic 
disorders is an experimental hypothesis tested at the 
limited scale by several independent labs. A major-
ity of these dietary interventions were about feeding 
prebiotics, which is described as the food supple-
ments for the gut microbiome. Typically fibers, indi-
gestible to host, are used as prebiotics and have been 
found to have positive impact on specific members 
of gut-microbiome.18,19,20
BIOACTIVE DIETARY MOLECULES
Food is obviously our prime source of essen-
tial nutrients and plays a predominant role in 
1Department of Food Science and Technology,
2Department of Statistics, 
3School of Biological Science, 
4Center for Biotechnology, 
University of Nebraska, Lincoln, NE, USA. 
*Correspondence to:  
Rohita Sinha, Ph.D., Research 
Assistant Professor, University of 
Nebraska-Lincoln, Department of 
Food Science & Technology 
rsinha2@unl.edu
Cite This Article: Sinha, R.,  
Clarke, J., Riethoven, J. 2018. 
Metabolic Syndrome, Gut 
Microbiome and Dietary Bioactive 
Peptides, an Unexplored 
Triad. Diabesity 4(1): 1-4. 
DOI: 10.15562/ diabesity.2018.45
Volume No.: 4
Issue: 1
First page No.: 1
RH_Author: XXX
Doi: diabesity.2018.45
Perspectives
Metabolic Syndrome, Gut Microbiome and Dietary 
Bioactive Peptides, an Unexplored Triad
Rohita Sinha,1* Jennifer Clarke,1,2 Jean-Jack Riethoven3,4
Metabolic Syndrome, Gut Microbiome  ... Rohita Sinha, et al.
2 Diabesity 2018; 4(1): 1-4. doi: 10.15562/diabesity.2018.45 www.diabesity.ejournals.ca
determining our health status. While existing liter-
ature has a comprehensive report about the health 
benefits of various food articles, our knowledge 
about the molecular-mechanisms exerting these 
benefits is still at its infancy. Advanced techniques 
such as Next generation sequencing, has certainly 
helped us untangle the complex association between 
diet and the gut microbiome, which consequently 
affects the physiological state of the human being. 
One of the these less explored class of bioactive 
molecules and molecular-mechanisms are dietary 
peptides and their mode of action. 
Bioactive peptides:
Bioactive peptides are part of scientific exploration 
since the last three decades; and almost all levels of 
living entities such as microbes, plants, and animals 
either produce or have proteins that are digested 
to bioactive peptides by proteases.21 For example, 
serum albumin treated with trypsin produces 
peptides with antihypertensive and antioxidant 
activities, similarly plant sources such as wheat, rice, 
oat, sorghum etc. were reported to be rich sources 
of bioactive peptides.22,23 There are several reports of 
milk and other dairy products as a reservoir of bioac-
tive peptides.24,25 The range of activities of known 
bioactive peptides are comprised of antihyperten-
sive, antioxidant, anti-inflammatory and antimi-
crobial actions.26,27 Among these, the antimicrobial 
activity of bioactive peptides draws a lot of attention, 
as the frequency of microbial resistance to known 
drugs is increasing. Antimicrobial peptides (AMP) 
originated from the animal system are considered 
as the first line of defence in the area with constant 
exposure to pathogenic microbes. AMPs are natural 
product of several prokaryotes and eukaryotes and 
so far more than 5000 such peptides are reported 
in the literature.28,29,30 The most common mode 
of action of AMPs is dependent on their ability to 
interact with the negatively charged cell surface of 
the microbes and then insert into the hydrophobic 
cell membrane and disrupt it either by creating pores 
or making clusters. There is another class of AMPs 
which are absorbed (cell penetration or endocytosis) 
by the microbial cells and exert their activities by 
disrupting essential biochemical pathways.31,32,33,34 
Antimicrobial peptides with intracellular 
activities
Beyond the common perception of antimicrobial 
peptides acting as microbial cell-surface disrupter, 
there is ample evidence of peptides with intracellu-
lar activities.32,33,34 Following are examples of anti-
microbial peptides with intracellular activities:
Buforin I/II: Buforin-I is a 39 amino-acid long 
AMP derived from the stomach of the Bufo bufo 
gargarizans, an Asian toad.35 While Buforin-I 
has a broad spectrum antimicrobial activity, its 
21  amino-acid long derivative (Buforin-II) was 
found to be more potent. Contrary to the majority 
of known AMPs, Bufroin-I/II interacts with DNA 
& RNA to kill the microbes.36
Apidaecin type peptides: These peptides are 
generally 18-20 amino acids long and were isolated 
from honeybees.37,38 Predominantly uptaken 
through the ABC transporters of Gram-negative 
bacteria, Apidaecin peptides bind to ribosomes to 
disrupt bacterial protein synthesis.39
Bac7: A 60 amino-acids long peptide derived 
from the bovine neutrophils. Bac7 does not disrupt 
bacterial cell membrane, but rather travels to the 
cytoplasm with the help of peptide transporter 
protein Sbm-A. Bac7 kills bacterial cells by target-
ing ribosomes and hindering protein synthesis.40 
Indolicidin: It is a 13 amino-acids long peptide 
derived from the bovine neutrophils. It interacts 
with double stranded DNA molecules to arrest 
transcription, replication and consequently kills the 
bacterial cell.41,42
PEPTIDES AS NATURAL INHIBITORS 
OF PROTEIN-PROTEIN INTERACTIONS 
(PPIS)
As discussed above, there are several yet to be 
defined biochemical interactions or ’mode of 
actions’ of bioactive peptides — competitive inhi-
bition of vital protein-protein interactions is one 
of them. Protein-protein interactions (PPI) are 
essential to most of the vital cellular-pathways such 
as transcription, translation, signal transduction, 
host-pathogen interactions, etc.,43 and are emerg-
ing as a new class of drug targets. Thus, recently 
we have seen a wider effort to develop an array 
of PPI inhibitors (antibodies, small-ligands and 
peptides)44,45,46 and extend the concept to develop 
microbial PPI inhibitors as a new class of antimi-
crobial agents. 
Cellular protein-protein interaction networks are 
marked by the presence of hub proteins — proteins 
which interact with multiple individual proteins. 
Such proteins are vital to entire networks, and conse-
quently are prime targets for the antimicrobial agents. 
Protein-protein complexes are characterized by 
larger interfaces, where the interactions are mediated 
by several short fragments (peptides). Few of these 
interfacial peptides called hot-segments, contribute 
most to the total binding energy of these complexes. 
The hot-segments are used as  lead-molecules to 
develop new PPI inhibitors.47,48,49 Few of the several 
such successful cases are inhibitory peptides for P53 
& MDM250 and XIAP & Smac interactions;51 there 
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are also instances of peptides inhibiting oligomeriza-
tion of membrane proteins.52,53
TRIAD OF METABOLIC DISORDERS, 
GUT MICROBIOME AND DIETARY 
PEPTIDES
While a majority of dietary peptides are fully 
digested and absorbed in the small intestine, there 
is a significant fraction which escapes and reaches 
the large intestine (a major reservoir of the gut 
microbes) to either further be digested by microbial 
enzymes or engulfed by them. As detailed above, 
there are multiple instances of bacterial absorp-
tion of peptides leading to the inhibition of vital 
microbial pathways and cell death. In the light of 
this statement, it would be an intriguing thought 
to evaluate the antimicrobial activity of dietary 
peptides reaching the large intestine.
Given the the ability of peptides, sharing sequence 
identity with hot-segments at protein-protein inter-
faces, to competitively inhibit PPI; we propose 
an intriguing idea of exploring the interaction of 
dietary peptides (peptides originating from diges-
tion of dietary proteins in the human gastrointesti-
nal tract) with gut microbes and test if such peptides 
can be subcategorized as new class of antimicrobial 
peptides. There are several unfathomed aspects of 
these putative interactions, such as the optimum 
length and composition of peptides for microbial 
absorption or surface binding, minimum inhibitory 
concentration of peptides, dietary proteins which are 
a rich source of such bioactive peptides, and finally 
fast and robust computational protocols to predict 
bioactive peptides and evaluate their ability to inhibit 
protein-protein interactions. We hope that with our 
increasing understanding of the composition of the 
gut microbiome and its association with human 
health, there would be significant interest among the 
scientific community about the interaction of gut 
microbes and dietary peptides. A natural extension 
of it would be the targeted dietary peptide based 
modulation of the gut microbiome to treat metabolic 
disorders. Authors, part of the current manuscript, 
are currently performing in vitro experiments to 
explore the absorption and microbial pathway inhib-
itory activities, of dietary peptides. 
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